Literature DB >> 30222123

Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients.

Konstantinos P Tsioufis1, Lida Feyz, Kyriakos Dimitriadis, Dimitris Konstantinidis, Dimitrios Tousoulis, Michiel Voskuil, Felix Mahfoud, Joost Daemen.   

Abstract

AIMS: The aim of this study was to evaluate the safety and performance of renal nerve stimulation (RNS) for diagnostic mapping of the renal nerves. METHODS AND
RESULTS: In this first-in-man study, twenty hypertensive patients underwent RNS using the ConfidenHT system. Bilateral stimulations were performed at three to four sites per artery at 2 and 4 mA. The primary endpoint was change in systolic blood pressure (SBP). Mean office blood pressure was 156/89 mmHg. No periprocedural adverse events occurred. Stimulation with 2 mA resulted in a maximum change of 8.3±6.3 mmHg in SBP (based on 119 stimulations; p<0.001), while stimulating with 4 mA resulted in a maximum change of 10.1±7.8 mmHg (based on 61 stimulations; p<0.001). The mean change in SBP did not vary between mid, distal or branch sites when stimulating at 2 mA but was significantly higher at ostial (23±14 mmHg) than at non-ostial locations (9±7 mmHg) when stimulating at 4 mA (p=0.003).
CONCLUSIONS: RNS can be performed safely and effectively along the renal artery and results in a large variation in temporary BP changes per patient and per anatomic location. RNS might help in optimising treatment effect and selecting potential responders to renal sympathetic denervation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30222123     DOI: 10.4244/EIJ-D-18-00536

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  6 in total

1.  Aorticorenal Ganglia Pacing: A Step Forward in Unblinding Renal Denervation Procedures?

Authors:  Felix Mahfoud; Thomas Tschernig; Elazer R Edelman
Journal:  JACC Cardiovasc Interv       Date:  2019-06-24       Impact factor: 11.195

Review 2.  Renal denervation: basic and clinical evidence.

Authors:  Kenichi Katsurada; Keisuke Shinohara; Jiro Aoki; Shinsuke Nanto; Kazuomi Kario
Journal:  Hypertens Res       Date:  2021-12-17       Impact factor: 3.872

Review 3.  The position of renal denervation in treatment of hypertension: an expert consensus statement.

Authors:  V J M Zeijen; A A Kroon; B H van den Born; P J Blankestijn; S C A Meijvis; A Nap; E Lipsic; A Elvan; J Versmissen; R J van Geuns; M Voskuil; P A L Tonino; W Spiering; J Deinum; J Daemen
Journal:  Neth Heart J       Date:  2022-08-24       Impact factor: 2.854

Review 4.  Joint UK societies' 2019 consensus statement on renal denervation.

Authors:  Melvin D Lobo; Andrew S P Sharp; Vikas Kapil; Justin Davies; Mark A de Belder; Trevor Cleveland; Clare Bent; Neil Chapman; Indranil Dasgupta; Terry Levy; Anthony Mathur; Matthew Matson; Manish Saxena; Francesco P Cappuccio
Journal:  Heart       Date:  2019-07-10       Impact factor: 5.994

Review 5.  Renal Denervation in Asia: Consensus Statement of the Asia Renal Denervation Consortium.

Authors:  Kazuomi Kario; Byeong-Keuk Kim; Jiro Aoki; Anthony Yiu-Tung Wong; Ying-Hsiang Lee; Nattawut Wongpraparut; Quang Ngoc Nguyen; Wan Azman Wan Ahmad; Soo Teik Lim; Tiong Kiam Ong; Tzung-Dau Wang
Journal:  Hypertension       Date:  2020-02-03       Impact factor: 10.190

Review 6.  Present Evidence of Determinants to Predict the Efficacy of Renal Denervation.

Authors:  Hao Zhou; Yanping Xu; Weijie Chen; Liang Wang; Huaan Du; Hang Liu; Zhiyu Ling; Yuehui Yin
Journal:  Int J Hypertens       Date:  2022-08-12       Impact factor: 2.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.